Global Systemic Lupus Erythematosus Market- 2020-2027

Global Systemic Lupus Erythematosus Market- 2020-2027

Global Systemic Lupus Erythematosus Market is segmented By Drug Class (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, Others), By Mode of Delivery (Intravenous, Sub-cutaneous, Oral, Topical), By Distribution Channel (Retail pharmacies, Hospitals, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027
Market Overview
The Global Systemic Lupus Erythematosus Market is expected to grow at a CAGR of 7.0% during the forecasting period (2020-2027).
Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune disease with signs and symptoms that can affect any part of the body, such as skin, joints, and organs.
The disease is more common in women and usually affects individuals in the age group of 25 to 45.
At least 5 million people worldwide suffer from a form of lupus.
Market Growth and Trends:
The Global Systemic Lupus Erythematosus market is expected to reach USD 3.2 billion by 2025.
Primary market drivers include increased incidence of autoimmune diseases, a robust pipeline with different molecules in clinical development, increasing R&D investment in SLE drugs and raising awareness among people about SLE treatments.
However, lack of understanding about the pathogenesis of the disease, use of off-label drugs, slow market uptake of Benlysta is some of the significant factors affecting market growth.
A high level of unmet need exists in the SLE market for therapies that can reduce the use of corticosteroids and improve the quality of life of patients.
Market Segmentation
Global Systemic Lupus Erythematosus market report segments the market by drug class, by mode of delivery, and by region.
Based on the type of treatment provided, the market is segmented into Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic And Immunosuppressive Drugs, Biologics. Anti-malarials, steroids, and other immunosuppressive agents will continue to dominate the market.
Based on the distribution channel by which drugs can be obtained, the market is segmented into hospitals, retail pharmacies, and online pharmacies.

Hospitals, followed by retail pharmacies will account for significant market share.
Based on the mode of delivery, the market is further segmented into oral, intravenous, topical and subcutaneous routes.
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

North America accounts for a dominant share regarding revenue, followed by Europe due to a high incidence rate of SLE.
In the North America region, the US is the largest market.
The Lupus Foundation of America estimates that 1.5 million Americans have a form of lupus.
Asia-Pacific presents the enormous opportunity for market expansion due to the increasing prevalence of asthma that has resulted from high levels of air pollution, rapid urbanization, the rise in smoking population, and changing lifestyle.
The Scope of the Report
The report also profiles the following companies in Systemic Lupus Erythematosus market – Anthera Pharmaceuticals Inc., Eli Lilly, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.
By Drug Class
Antimalarial Drugs
Non-Steroidal Anti-Inflammatory Drugs
Cytotoxic And Immunosuppressive Drugs
Biologics
Others
By Mode of Delivery
Intravenous
Sub-cutaneous
Oral
Topical
By Distribution channel
Hospitals
Retail pharmacies
Online pharmacies
By Region
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World
Why purchase the report?
Visualize the composition of Systemic Lupus Erythematosus market across each indication, regarding type and treatment options, highlighting the vital commercial assets and players.
Identify commercial opportunities in the market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the Systemic Lupus Erythematosus market – level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for crucial Systemic Lupus Erythematosus products of all major market players
Target Audience:
Equipment Suppliers/ Buyers
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers


Chapter 1 – Global Systemic Lupus Erythematosus Market – Methodology and Scope
1.1 Research Methodology
1.2 Scope of the Report
Chapter 2 – Global Systemic Lupus Erythematosus Market – Trends
2.1 Key Trends & Developments
Chapter 3 – Global Systemic Lupus Erythematosus Market – Industry Analysis
3.1 Market Drivers
High Prevalence of Autoimmune Disease
Strong pipeline
Increasing R&D investment on SLE drugs
3.2 Market Restraints
High use of off-label drugs
Slow market uptake of Benlysta
Threats and Opportunities
Porter’s 5 Forces
Chapter 4 – Global Systemic Lupus Erythematosus Market – Market Analysis
4.1. Systemic Lupus Erythematosus Market – By Drug Class
Antimalarial Drugs
Non-Steroidal Anti-Inflammatory Drugs
Cytotoxic And Immunosuppressive Drugs
Biologics
Others
Systemic Lupus Erythematosus Market – By Mode of Delivery
Intravenous
Sub-cutaneous
Oral
Topical
Systemic Lupus Erythematosus Market – By Distribution Channel
Retail pharmacies
Hospitals
Online Pharmacies
Chapter 5 – Global Systemic Lupus Erythematosus Market – Geographical Analysis
5.1. North America
5.1.1. The USA
5.1.2. Canada
5.1.3. Mexico
5.2. Europe
5.2.1. Germany
5.2.2. France
5.2.3. The UK
5.2.4. Italy
5.2.5. Spain
5.2.6. Rest of Europe
5.3. Asia Pacific
5.3.1. China
5.3.2. Japan
5.3.3. India
5.3.4. Australia
5.3.5. Rest of Asia Pacific
5.4. South America
5.4.1. Brazil
5.4.2. Argentina
5.4.3. Rest of South America
5.5 Rest of the World
Chapter 6 – Global Systemic Lupus Erythematosus Market – Competitive Landscape
6.1. Market Share Analysis
6.2. Mergers and Acquisitions Analysis
6.3. New Product Launches
Chapter 7 – Global Systemic Lupus Erythematosus Market – Company Profiles
Anthera Pharmaceuticals Inc.
Eli Lilly
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
Pfizer Limited
Sanofi
Lycera Corporation
Bristol-Myers Squibb
ImmuPharma Plc
Merck KGaA
Chapter 8 – Global Systemic Lupus Erythematosus Market – Appendix
8.1 Sources
8.2 List of Tables
8.3 Expert Panel Validation
8.4 Disclaimer
8.5

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings